|
Market Closed -
Nasdaq Helsinki
19:00:00 21/08/2026 +03
|
After hours 22:15:41 | |||
| 79.25 EUR | +0.25% |
|
79.28 | +0.03% |
| 08-10 | Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial | MT |
| 08-10 | Orion partner's phase 3 study with levosimendan missed its goals | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORION OYJ | Other Pharmaceuticals | +0.25% | +2.39% | +24.51% | +14.36% | +131.25% | 13B |  | | |
- Stock Market
- Stocks
- ORNBV Stock
- Charts Orion Oyj
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
